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Prevalence of cardiovascular disease and evaluation of
standard of care in type 2 diabetes: a nationwide study in
primary care
Jorgen Rungbya, Morten Schoub, Per Warrerd, Lars Yttee and
Gert S. Andersenc
Objective Cardiovascular disease (CVD) complicates type
2 diabetes. Empagliflozin and liraglutide have demonstrated
improved survival in patients with type 2 diabetes and
established CVD. We assessed prevalence and standard of
care of patients with type 2 diabetes and established CVD
managed in primary care.
Patients and methods A total of 129 general practitioners
in both rural and urban areas, responsible for 348 373
patients, identified their patients with type 2 diabetes. The
identification was based on a search for International
Classification of Primary Health Care 2 codes in the general
practitioners’ electronic patient record systems. Patients
with concomitant CVD were identified and characterized.
Results A total of 17 113 (4.9%) patients were diagnosed
with type 2 diabetes. Type 2 diabetes with concomitant CVD
was found in 3665 (21.4%) patients, with their mean age
being 72 years, and 34.6% were women. Mean estimated
glomerular filtration rate was 68.2ml/min, and 22.2% had
microalbuminuria or macroalbuminuria. Standard of care
was fair: mean glycated hemoglobin was 52.3mmol/mol
(Diabetes Control and Complications Trial= 6.9%), mean
blood pressure was 131.4/75.7mmHg, and mean low-
density lipoprotein cholesterol was 2.0mmol/l.
Conclusion In a nationwide database survey in primary
care, the prevalence of CVD in patients with type 2 diabetes
was high (21.4%). Standard of care was largely in
accordance with national guidelines. Identification of
eligible patients is possible with existing electronic patient
record systems. Identifying this high-risk subgroup of
patients with type 2 diabetes and optimizing their treatment
might add further cardiovascular benefits as suggested by
recent cardiovascular outcome trials. Cardiovasc
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Introduction
Patients with diabetes are at increased risk of developing a
number of serious microvascular and macrovascular com-
plications [1]. Across all ages, the relative risk of developing
cardiovascular disease (CVD) is ∼ 2 for patients with dia-
betes compared with the general population [2,3], and
CVD contributes significantly to the increased, albeit
decreasing over time, mortality rate [4,5]. Still, CVD
accounts for up to 50% of deaths in patients with diabetes
[4]. Furthermore, the prevalence of diagnosed type 2
diabetes is constantly rising from 415 million globally in
2015 to an estimated 642 million in 2025 [6]. In Denmark,
290 000 were diagnosed with type 2 diabetes in 2012, and
a further 180 000 were estimated to be undiagnosed [7].
Until recently, UK Prospective Diabetes Study (UKPDS)
[8] and PROspective pioglitAzone Clinical Trial In
macroVascular Events (PROactive) [9] were the only
interventional studies on glucose-lowering therapies
demonstrating positive effects on cardiovascular (CV)
outcomes. However, both studies have limitations. In
UKPDS, the demonstrated effect was achieved in a small
subgroup of overweight patients treated with metformin
compared with conventional, primarily nonpharma-
cological therapy. In the PROactive study, the secondary
3P major adverse cardiac events endpoint was sig-
nificantly reduced, but the heterogeneous composite
primary endpoint failed to reach significance. In 2015 and
2016, two cardiovascular outcome trials (EMPA-REG
OUTCOME [10] and LEADER [11]) evaluating the
long-term CV safety according to the Food and Drug
Administration recommendations for new antidiabetic
drugs were published (http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
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assessing the safety of the sodium–glucose cotransporter
2 (SGLT2) inhibitor empagliflozin, and LEADER,
assessing the safety of the glucagon-like peptide 1
receptor agonist liraglutide, the addition of empagliflozin
or liraglutide to standard therapy of type 2 diabetes leads
to a significant reduction of the primary composite end-
point of CV death, nonfatal myocardial infarction, and
nonfatal stroke, compared with placebo. Reduction of the
primary endpoint was predominantly driven by a reduc-
tion in CV death in both studies. Moreover, empagli-
flozin also demonstrated a significant reduction in the
risk for hospitalization owing to heart failure [12].
On the basis of the positive findings in these outcome
studies, we decided to carry out a nationwide survey of
patients with type 2 diabetes and established CVD in
general practice, where most patients with type 2 dia-
betes in Denmark are managed. The aims of the survey
were to record the prevalence of concomitant CVD in a
general practice population of patients with type 2 dia-
betes and to describe the standard of care in these
patients. We searched the patient files for a diagnosis of
myocardial infarction, ischemic heart disease with and
without angina pectoris, heart failure, transitory cerebral
ischemia or stroke, or atherosclerosis/peripheral vascular
disease. In addition, atrial fibrillation, hypertension,
albuminuria, diabetic retinopathy, demographic data,
glycaemic status, kidney function, lipid status, and blood
pressure were recorded along with information about
current treatment of the patients.
Patients and methods
General practices using one of the five electronic patient
record systems were approached. All five systems are certi-
fied in accordance with standards for IT systems in Danish
Healthcare as governed by the Danish Medicines Agency.
The five systems are used by ∼72% of Danish general
practitioners (GPs). To obtain a broad sample, 526 general
practices of varying size from all regions of Denmark, rural as
well as urban areas, were approached, representing ∼1 out
of 4 (28.5%) practices in Denmark. The included practices
represented different organizational models ranging from
solo practices to group settings (Fig. 1).
The practices were invited to participate by Boehringer
Ingelheim Danmark A/S (BI, Denmark) sales repre-
sentatives during the time period 3 May 2016–30th June
2016. GPs accepting the invitation reported their
cooperation with BI to the Danish Medicines Agency.
The study was approved by the Danish Data Protection
Agency (no. H-16023132). In Denmark, registry studies,
such as the present one, do not require approval
from research ethics committees or from the Danish
Medicines Agency.
Identification of patients with type 2 diabetes was made by
a search in the GPs’ electronic patient record systems using
the International Classification of Primary Health Care 2
(ICPC-2) coding system which is anchored in the ICD-10
code system. The ICPC-2 system is fully integrated with
ICD-10, and the conversion of ICD-10 codes to ICPC-2 is
automatic. An accredited standard has been developed for
the use of ICPC-2 in Danish primary healthcare electronic
patient record systems. In close to 96% of cases, conversion
is unambiguous. In the remaining cases, possible matches
are suggested for the GP to choose from. In cases, where a
patient is diagnosed by the GP and thus does not have an
ICD-10 code, the GP assigns an ICPC-2 code. The primary
inclusion criterion was a record of the ICPC-2 – DK diag-
nosis code T90 (type 2 diabetes), and secondly, a record of
at least one of the seven ICPC-2 – DK diagnosis codes for
CVD was required:
(1) K74 – Ischemic heart disease with angina pectoris.
(2) K75 – Acute myocardial infarction.
(3) K76 – Ischemic heart disease without angina pectoris.
(4) K77 – Heart failure.
(5) K89/K90 – Transient cerebral ischemia/stroke.
(6) K92 – Atherosclerosis/peripheral vascular disease.
In addition, the following nonrequired diagnoses were
recorded: atrial fibrillation (K78) and hypertension (K85/
K86/K87).
After primary identification, the following patients were
excluded:
(1) Deceased patients.
(2) Patients who were passing through or had moved to
another clinic.
(3) Patients whose diabetes was managed in a hospital
setting.
(4) Patients who had a kidney transplant or were on
dialysis treatment.
Included patients were numbered sequentially for each
GP. If more than 20 patients qualified, 20 patients were
selected for inclusion by a computerized random draw.
During the period 15 August to 20 October 2016, data
were recorded through electronic case record forms spe-
cifically designed for the study. Data were entered by a
web-client (Angular 2, v 4.0). For data quality assurance,
the case record form system had built-in validation
checks to capture and question implausible data entries.
Data were entered in the case record forms by repre-
sentatives from BI based on the GPs’ ‘oral reading’ from
the electronic patient record system. Thus, only the GP
had direct access to the electronic patient record system.
Data were processed and presented by means of
descriptive statistics. There was no hypothesis testing.
Data are presented as mean ± SD (range) or as propor-
tions of patients (%). Handling and analysis of the data
were done in Django 1.10 on an Ubuntu 14.04 server.
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Results and discussion
Materials
A total of 526 GPs were invited to participate, of whom
131 accepted and 129 provided valid data. Regarding
overview of the data flow, refer to Fig. 1 (consort). The
included GPs represented 348 373 patients, where 17 113
(4.9%) were diagnosed with type 2 diabetes, and 4198
(24.4%) of these had concomitant CVD. After exclusion
of patients managed in a hospital setting or who had a
kidney transplant or were on dialysis treatment, 3665
(21.4%) patients were eligible, representing the pre-
valence of patients with type 2 diabetes and concomitant
CVD in general practice. Computerized random selection
of 20 patients if more than 20 patients qualified in a clinic
excluded 1174 patients, and data cleaning excluded
another 488 patients, resulting in 2003 patients being
included in the analysis (Fig. 1). The selection of 20
patients was truly random, based only on patient
Fig. 1
526 GPs invited
146 GPs accepted invitation
15 GPs withdrew before data-search 
131 GPs recorded data
2 GPs with invalid data excluded
129 GPs with valid data 56 GPs from solo practices
21 GPs from collaboration practices
45 GPs from partnership practices with responsibility for own 
patients
7 GPs from partnership practices with shared responsibility for 
patients
Overall 348,373 patients managed 
by 129 GPs
17,113 (4.9%) patients with a T90 
diagnosis (T2DM)
4,178 (24.4%) patients with at least 
one prespecified ICPC-2-CV 
diagnosis code
490 (11.7%) patients managed in hospital
23 (0.6%) patients with a kidney transplant or on dialysis 
treatment
3,665 (21.4%) patients qualified
1,174 randomly excluded for GP clinics with more than 20 
qualified patients
2,491 patients chosen for data 
recording
299 patients excluded after recording of data
Deceased
Passing through
Managed elsewhere
Wrongly diagnosed
Other reasons
2,192 patients recorded in the 
database
189 patients excluded before analysis
Lacking required ICPC-2 -CV diagnosis codes
Only atrial fibrillation 
Only hypertension 
Only atrial fibrillation and hypertension
2,003 patients included in final 
analysis
Consort diagram. CV, cardiovascular; GP, general practitioner; ICPC-2, International Classification of Primary Health Care 2; T2DM, type 2 diabetes mellitus.
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identification numbers before any data were recorded.
Thus, for exclusion of patients, there were no con-
siderations of sex, age, duration of diabetes, or other data.
Demography and clinical status
Patient characteristics are shown in Table 1. Most patients
were men (65.4%), age was 72 years, and BMI was 30.1
kg/m2. Time since diagnosis of type 2 diabetes was less than
5 years in 28.8% and more than 10 years in 33.7% of the
patients. Overall, 51 were smokers or exsmokers. Glycated
hemoglobin (HbA1c) was 52.3mmol/mol [Diabetes Control
and Complications Trial (DCCT)=6.9%], 23.5%
had HbA1c>58mmol/mol (DCCT=7.5%). Estimated
glomerular filtration rate (eGFR) was 68.2ml/min/1.73m2,
36% had eGFR less than 60ml/min/1.73m2. Albuminuria
(Albumin creatinine ratio>30mg/g) was present in 22.2%.
Diabetic retinopathy was diagnosed in 6.2% of the patients.
Status regarding albuminuria and retinopathy was unknown
for approximately one-third of the patients. Moreover, 90%
of the patients had a diabetes control in the past year.
Systolic and diastolic blood pressure was 131.4 and
75.7mmHg, respectively. low-density lipoprotein choles-
terol was 2.0mmol/l and high-density lipoprotein cholesterol
was 1.2mmol/l.
Almost 22% had no pharmacological glucose-lowering
treatment, 47.5% were receiving monotherapy, and
30.1% were on dual or triple therapy. Insulin was used by
19.5% either as monotherapy or in combination
(Table 2). Incretin-based therapy was used by 12.4% and
SGLT2-inhibitor therapy by 4%. Moreover, 82% had
cholesterol-lowering treatment, almost exclusively a
statin; 94.4% had anticoagulant/antiplatelet treatment
(50.1% aspirin); 66.1% were receiving ACE-I or ARB
therapy; and 30.3% a loop diuretic (Table 2).
Cardiovascular disease
The mean number of CV diagnoses per patient was 1.5,
ranging from 1 to 5 (Table 3). The most frequently
registered CV diagnosis was ischemic heart disease with
angina pectoris (32.9%) followed by transient cerebral
ischemia or stroke (30.6%), myocardial infarction (25.7%),
ischemic heart disease without angina pectoris (20.5%),
and atherosclerosis/peripheral vascular disease (19.3%)
(Table 3). Atrial fibrillation was diagnosed in 18.8% and
hypertension in 66.3% of the patients.
Heart failure was diagnosed in 22.3% of the patients,
predominantly men (61.9%). The age of patients with
heart failure was 73.6 years compared with 71.5 years for
patients without (Supplementary Table 2, Supplemental
digital content 1, http://links.lww.com/CAEN/A17). Patients
with heart failure had a slightly higher BMI. The level of
lipidemic control (mean cholesterol concentrations) was
approximately the same in patients with and without
heart failure.
Compared with patients without heart failure, atrial
fibrillation was more frequent with heart failure (13.4 vs.
37.4%), whereas the distribution of ischemic heart
Table 1 Demographic/background data
Men 1309 (65.4)
Age (years) 72.0 ±10.4 (30–100)
Weight (kg) (n=1563) 88.1 ±19.7 (43.0–210.0)
BMI (n=1297) 30.1 ± 5.9 (16.7–67.0)
Smoking (daily/occasionally/stopped/never) (%) 16.9/0.7/33.8/31.8
0–4 years since T2DM diagnosis 576 (28.8)
5–10 years since T2DM diagnosis 720 (35.9)
>10 years since T2DM diagnosis 676 (33.7)
Time since T2DM diagnosis unknown 31 (1.5)
T2DM control at GP within the past year 1799 (89.8)
HbA1c (mmol/mol) (n=1988) 52.3 ± 13.4 (25–138)
HbA1c≥58mmol/mol 470 (23.5)
Systolic blood pressure (mmHg) (n=1930) 131.4 ±15.3 (78–202)
Diastolic blood pressure (mmHg) (n=1930) 75.7 ±9.9 (45–118)
Systolic blood pressure>130mmHg 895 (44.7)
Total cholesterol (mmol/l) (n=1977) 4.0 ±1.1 (1.8–10.1)
LDL cholesterol (mmol/l) (n=1916) 2.0 ±0.9 (0.2–7.4)
HDL cholesterol (mmol/l) (n=1978) 1.2 ±0.4 (0.1–4.7)
LDL cholesterol>1.8 mmol/l 946 (47.2)
eGFR (ml/min/1.73 m2) (n=1936) 68.2 ± 20 (6–91)
eGFR≥60ml/min/1.73 m2 1282 (64.0)
Albuminuria status (normo/micro/macro/
unknown) (%)
45.8/18.6/3.6/32.0
Diabetic retinal changes (present/none/
unknown) (%)
6.2/64.5/29.3
Data are presented as number of patients (%) and mean ±SD (range).
eGFR, estimated glomerular filtration rate; GP, general practitioner; HbA1c,
glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
T2DM, type 2 diabetes mellitus.
Table 2 Standard of care
Glucose-lowering treatment Number of patients [n (%)]
Metformin 1098 (54.8)
Nonpharmacological treatment 436 (21.8)
Insulin 391 (19.5)
Sulfonylurea 158 (7.9)
DPP-4 inhibitor 140 (7.0)
GLP-1 receptor agonist 108 (5.4)
SGLT2 inhibitor 80 (4.0)
Metformin +DPP-4 inhibitor 167 (8.3)
Metformin +SGLT2 inhibitor 10 (0.5)
Others 2 (0.1)
Number of patients on 1 drug treatment 951 (47.5)
Number of patients on 2 drugs treatment 478 (23.9)
Number of patients on 3 drugs treatment 124 (6.2)
Number of patients on 4 drugs treatment 13 (0.6)
Treatment for hypertension and/or heart failure
β-Blocker 980 (48.9)
ACE inhibitor 762 (38.0)
Calcium antagonist 625 (31.2)
ARBs 563 (28.1)
Others 21 (1.0)
Diuretic treatment
Loop diuretics 607 (30.3)
Thiazide diuretics 519 (25.9)
Others 215 (10.7)
Cholesterol-lowering treatment
Statins 1568 (78.3)
Fibrate 7 (0.3)
Others 72 (3.6)
Anticoagulant/antiplatelet treatment
Aspirin 1003 (50.1)
Others 888 (44.3)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers;
DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; SGLT2,
sodium–glucose cotransporter 2.
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disease was almost equal between patients with and
without heart failure (Supplementary Table 2,
Supplemental digital content 1, http://links.lww.com/
CAEN/A17). Patients with heart failure had fewer cerebral
events (14.8 vs. 35.1%), lower blood pressure (systolic:
127.2 vs. 132.6 mmHg, diastolic: 74.1 vs. 76.1 mmHg),
and lower eGFR (62.3 vs. 69.9 ml/min/1.73 m2)
(Supplementary Table 2, Supplemental digital content 1,
http://links.lww.com/CAEN/A17). More patients with heart
failure than without were receiving insulin (22.9 vs.
18.6%), β-blockers (65.2 vs. 44.3%), and diuretics (77.1
vs. 50.2%), whereas fewer received metformin (55.8 vs.
65.8%) (Supplementary Table 2, Supplemental digital
content 1, http://links.lww.com/CAEN/A17). The propor-
tion of patients on sulfonylurea treatment was similar
with and without heart failure (7.6 vs. 8.0%).
In all, 61% of the included patients had an ECG per-
formed within the past year, of which one-third was
abnormal (left ventricular hypertrophy: 16.2%; ST-
depression: 16%) (Table 4).
Diabetes duration and complications
CV complications were not only present in patients with a
long duration of diabetes. In 28.8% of the patients, type 2
diabetes was diagnosed less than 5 years ago, 35.9% of the
patients were diagnosed between 5 and 10 years earlier,
and 33.7% were diagnosed more than 10 years ago
(Table 1). In addition to the relatively early onset, the CV
complications occurred despite well-controlled lipidemia
and blood pressure (Table 1). In 29.8% of patients with
heart failure, type 2 diabetes was diagnosed less than
5 years ago, 31.4% were diagnosed with type 2 diabetes
between 5 and 10 years earlier, and 37.4% had diabetes for
10 years or more (Supplementary Table 2, Supplemental
digital content 1, http://links.lww.com/CAEN/A17).
In contrast to the macrovascular complications which
were equally prevalent regardless of known duration of
diabetes, the prevalence of microvascular complications
increased with the known duration of diabetes, particu-
larly after 10 years (diabetic retinopathy: <5 years 2.6%,
5–10 years 4.4%, and ≥ 10 years 11%; microalbuminuria:
<5 years 14.1%, 5–10 years 17.4%, and ≥ 10 years 24.1%;
macroalbuminuria: <5 years 2.8%, 5–10 years 2.9%, and
≥ 10 years 4.9%) (Supplementary Table 1, Supplemental
digital content 1, http://links.lww.com/CAEN/A17). Status
regarding retinopathy and albuminuria was lacking for a
relatively large proportion of the patients (24–37%,
respectively depending on diabetes duration).
The main finding of the survey was that 21.4% of
patients with type 2 diabetes in a nationwide survey in
general practice in Denmark have concomitant CV con-
ditions and are thus to be considered high-risk patients
(contrasting a frequency of 8% in the Danish population
as a whole, data from the Danish heart Association at
www.proxy.danskernessundhed.dk). Generally, patients with
type 2 diabetes were well managed in general practice
settings. The most common complication was ischemic
heart disease followed by cerebrovascular disease.
Furthermore, heart failure was common, as was hyper-
tension and atrial fibrillation. Thus, even in this relatively
well-controlled population of patients with type 2 dia-
betes, therapeutic considerations regarding CV comor-
bidities should be made, as a significant number of
life-years is still lost to CVD in these patients [2,13].
Importantly, the primary driver for the reductions in the
primary outcomes of the CV outcome studies with
empagliflozin and liraglutide was reduced CV mortality.
The present results suggest that 21.4% of patients with
type 2 diabetes in general practice may benefit from
knowledge gained from these recent CV outcome trials
[14]. In general, all CV outcome trials have confirmed
overall safety for the tested drugs (saxagliptin, alogliptin,
sitagliptin, lixisenatide, empagliflozin, and liraglutide).
For empagliflozin and liraglutide, even a benefit
extending to reduction in CV and all-cause mortality
when compared with placebo and added to standard of
care has been shown. Whether benefits demonstrated in
these studies extend beyond patients with already
established CVD remains unsettled. For heart failure,
only empagliflozin has demonstrated a decrease in the
need for hospitalization. Other drugs, except saxagliptin
Table 3 International Classification of Primary Health Care 2
cardiovascular diagnosis codes
ICPC-2 diagnosis
codes
Number of patients
[n (%)]
Mean number of ICPC-2 CV diagnoses 1.5 ±0.8 (1–5)
Required for inclusion
K74 Ischemic heart disease with angina
pectoris
659 (32.9)
K75 Acute myocardial infarction 515 (25.7)
K76 Ischemic heart disease without angina
pectoris
411 (20.5)
K77 Heart failure 446 (22.3)
K89/K90 Transitory cerebral ischemia/stroke 613 (30.6)
K92 Atherosclerosis/peripheral vascular
disease
387 (19.3)
Additional
K85, K86, K87 Hypertension 1327 (66.3)
K78 Atrial fibrillation 376 (18.8)
Data are presented as number of patients (%) and mean ±SD (range).
CV, cardiovascular; ICPC-2, International Classification of Primary Health Care 2.
Table 4 Electrocardiography status
Number of patients [n (%)]
ECG within the past year (yes/no/unknown
status) (%)
61.4/34/4.2
ECG (normal/abnormal/unknown) (%) 62.9/33.6/3.5
Left ventricular hypertrophy (yes/no/
unknown) (%)
16.2/83.3/0.5
ST-depression 66 (16)
No ST-depression 345 (83.5)
ST-depression unknown 2 (0.5)
Not categorized 216 (52.3)
Data are presented as number of patients (%).
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leading to an increase in hospitalization, have proved
neutral in this respect. Even though the outcome trials
may be difficult to interpret owing to their specific and
varying patient groups, their short duration and the
lack of head-to-head comparisons, we suggest that
they are taken into account when deciding on the
antihyperglycemic strategy in patients with CV
comorbidities.
Here, in a large group of patients with type 2 diabetes
and CVD, we report an acceptable concordance with
treatment goals of national guidelines. Blood pressure
(131/76 mmHg), lipid profile (low-density lipoprotein
cholesterol= 2.0 mmol/l), and HbA1c (52.3 mmol/mol;
DCCT= 6.9%) as well as the frequency of clinical
assessments were within reasonable standards of good
care. Overall, 16% of the patients with both type 2 dia-
betes and CV complications were still active smokers and
20% did not receive statins, definitely areas for
improvement.
In all, 22% of the patients were not in treatment with
glucose-lowering drugs, which is in contrast to Danish
guidelines suggesting that metformin should be given to
all. This is, however, in accordance with other studies
also showing a clinical inertia toward this general
recommendation [15]. Even though many patients had a
significant duration of type 2 diabetes (∼70% of patients
had diabetes for >5 years), almost half (47.5%) were
managed with one drug only, with metformin being the
most frequent oral drug. Approximately 20% of the
patients had insulin, which is a somewhat larger propor-
tion than generally expected in the Danish type 2 dia-
betes population (∼14%) [16], most likely reflecting the
fact that more than 33% of the patients had a diabetes
duration longer than 10 years. The use of sulfonylureas
was relatively low (7.9%), possibly reflecting the debate
on the cardiac safety profile of this drug class [17,18].
Relatively few patients were treated with the more
recently introduced drug classes, SGLT2 inhibitors,
glucagon-like peptide 1 receptor agonists, and dipeptidyl
peptidase 4 inhibitors.
Heart failure was frequent in patients with CVD (22%) in
primary care. Only 65–70% of the patients received an
ACE inhibitor or a β-blocker which may be explained by
a high frequency of patients with preserved ejection
fraction, which is supported by the high proportion of
women in this subgroup (38%). The patients with heart
failure were older and as expected a higher frequency
had atrial fibrillation. Based on recent published trials, it
may be speculated how patients with diabetes and heart
failure are best treated with respect to second-line ther-
apy for glycemic control. In the recent European guide-
lines for heart failure, empagliflozin has an IIA
recommendation for prevention of heart failure [19], and
trials evaluating SGLT2 inhibitors in patients with
echocardiographic phenotyped heart failure with and
without concomitant diabetes are ongoing. Two small
trials evaluating liraglutide in patients with documented
reduced left ventricular ejection fraction suggest that
patients with heart failure may not benefit from liraglu-
tide and that there might be a safety concern [20,21],
whereas in contrast, the larger well-powered LEADER
trial in a subgroup of patients with a ‘history of heart
failure‘ showed no signal of harm. At present, it may
therefore be suggested that empagliflozin can prevent
admission with congestion/heart failure in patients with
diabetes and CVD. However, we have to await results
from ongoing trials evaluating SGLT2 inhibitors in
patients with echocardiographic phenotyped heart failure
before it can be concluded that treatment with an
SGLT2 inhibitor improves long-term outcome in
patients with long-term heart failure with preserved and
reduced ejection fraction.
The study included data from practices covering a broad
geographical and organizational range. The study popu-
lation was large and identified based on the clearly
defined diagnosis codes in validated certified electronic
patient record systems, and data were systematically
collected. Furthermore, the retrospective nature of the
study secured data representing real-life management of
patients, preventing bias in selection of patients and
avoiding a strict protocol-defined treatment as seen in a
prospective setup.
Limitations include some degree of physicians’ sub-
jectivity in the coding. There may be some selection bias
related to practices choosing to participate having a par-
ticular interest in diabetes and CV comorbidity. The
overall quality of the data is subject to the extent of
follow-up and the quality of the GPs’ recording of patient
data. There is a lack of status regarding retinopathy and
albuminuria for approximately one-third of the patients
and some degree of lacking of data for BMI and smoking
status. Finally, the validity of the results does not extend
beyond the basis of patients correctly diagnosed and
recorded at the participating GP clinics.
Conclusion
In this nationwide database survey in primary care in
Denmark, the prevalence of CVD in patients with type 2
diabetes was high (21.4%). Standard of care was largely in
accordance with national guidelines. Identification of
eligible patients is possible with existing electronic
patient record systems. Identifying this high-risk sub-
group of patients with type 2 diabetes and optimizing
their treatment might add further CV benefits as sug-
gested by recent CV outcome trials.
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